ARCHIVES

NCI, Advisers Lean To Smaller Increases For R01a, Philosophy Of Spreading Money Among More Grants

This article is from The Cancer Letter archive.

Vol. 08 No. 03 | January 15, 1982

Download PDF Visit The Full Archive

Related Articles

Reimbursement Policy By Philadelphia Blue Cross Further Explained

April 21, 1989

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

Four Patients In Tamoxifin Treatment Trial Had Died of Uterine Cancer Prior To BCPT

April 29, 1994

Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says

November 28, 2014

John Niederhuber Named Acting NCI Director.

June 2, 2006

NIH On R29 Phase-Out; Grant Review Appeals Process Changed

January 23, 1998